These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 22878466)

  • 1. Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement.
    Schaefer M; Capuron L; Friebe A; Diez-Quevedo C; Robaeys G; Neri S; Foster GR; Kautz A; Forton D; Pariante CM
    J Hepatol; 2012 Dec; 57(6):1379-90. PubMed ID: 22878466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of pegylated interferon-α-2a treatment on mental health during recent hepatitis C virus infection.
    Alavi M; Grebely J; Matthews GV; Petoumenos K; Yeung B; Day C; Lloyd AR; Van Beek I; Kaldor JM; Hellard M; Dore GJ; Haber PS;
    J Gastroenterol Hepatol; 2012 May; 27(5):957-65. PubMed ID: 22142332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C treatment in patients with drug addiction: clinical management of interferon-alpha-associated psychiatric side effects.
    Schaefer M; Mauss S
    Curr Drug Abuse Rev; 2008 Jun; 1(2):177-87. PubMed ID: 19630716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis.
    Kalafateli M; Buzzetti E; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011644. PubMed ID: 28285495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.
    Schaefer M; Schmidt F; Folwaczny C; Lorenz R; Martin G; Schindlbeck N; Heldwein W; Soyka M; Grunze H; Koenig A; Loeschke K
    Hepatology; 2003 Feb; 37(2):443-51. PubMed ID: 12540795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of psychiatric diagnosis on treatment uptake and interferon side effects in patients with hepatitis C.
    Wu JY; Shadbolt B; Teoh N; Blunn A; To C; Rodriguez-Morales I; Chitturi S; Kaye G; Rodrigo K; Farrell G
    J Gastroenterol Hepatol; 2014 Jun; 29(6):1258-64. PubMed ID: 24955454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV/Hepatitis C virus-coinfected virologic responders to pegylated interferon and ribavirin therapy more frequently incur interferon-related adverse events than nonresponders do.
    Osinusi A; Rasimas JJ; Bishop R; Proschan M; McLaughlin M; Murphy A; Cortez KJ; Polis MA; Masur H; Rosenstein D; Kottilil S
    J Acquir Immune Defic Syndr; 2010 Mar; 53(3):357-63. PubMed ID: 20101190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring depression in patients undergoing alpha-interferon and ribavirin therapy for hepatitis C.
    Wright IA
    Gastroenterol Nurs; 2000; 23(6):275-80. PubMed ID: 11854972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects.
    Schaefer M; Hinzpeter A; Mohmand A; Janssen G; Pich M; Schwaiger M; Sarkar R; Friebe A; Heinz A; Kluschke M; Ziemer M; Gutsche J; Weich V; Halangk J; Berg T
    Hepatology; 2007 Oct; 46(4):991-8. PubMed ID: 17668880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychiatric implications of hepatitis-C infection.
    Giunta B; Somboonwit C; Nikolic WV; Rrapo E; Tan J; Shapshak P; Fernandez F
    Crit Rev Neurobiol; 2007; 19(2-3):79-118. PubMed ID: 19409058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction.
    Raison CL; Borisov AS; Broadwell SD; Capuron L; Woolwine BJ; Jacobson IM; Nemeroff CB; Miller AH
    J Clin Psychiatry; 2005 Jan; 66(1):41-8. PubMed ID: 15669887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuropsychiatric side effects of HCV therapy and their treatment: focus on IFN alpha-induced depression.
    Hauser P
    Gastroenterol Clin North Am; 2004 Mar; 33(1 Suppl):S35-50. PubMed ID: 15081102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon stimulated exonuclease gene 20 kDa links psychiatric events to distinct hepatitis C virus responses in human immunodeficiency virus positive patients.
    Katsounas A; Rasimas JJ; Schlaak JF; Lempicki RA; Rosenstein DL; Kottilil S
    J Med Virol; 2014 Aug; 86(8):1323-31. PubMed ID: 24782267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin.
    Mandorfer M; Payer BA; Scheiner B; Breitenecker F; Aichelburg MC; Grabmeier-Pfistershammer K; Rieger A; Trauner M; Peck-Radosavljevic M; Reiberger T
    Liver Int; 2014 Jan; 34(1):69-77. PubMed ID: 23890125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hepatitis C, interferon a and depression: main physiopathologic hypothesis].
    Vignau J; Karila L; Costisella O; Canva V
    Encephale; 2005; 31(3):349-57. PubMed ID: 16142050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychiatric aspects of hepatitis C treatment.
    Vrbanac DB; Buljan D; Sindik I; Gelo J; Sakoman LN
    Acta Clin Croat; 2013 Sep; 52(3):346-52. PubMed ID: 24558767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CTN-194 (PICCO): design of a trial of citalopram for the prevention of depression and its consequences in HIV-hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapy.
    Klein MB; Cooper C; Brouillette MJ; Sheehan NL; Benkelfat C; Annable L; Weston F; Kraus D; Singer J;
    Contemp Clin Trials; 2008 Jul; 29(4):617-30. PubMed ID: 18262853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated interferon-alpha2b plus ribavirin therapy in patients with hepatitis C and psychiatric disorders: results of a cohort study.
    Lang JP; Melin P; Ouzan D; Rotily M; Fontanges T; Marcellin P; Chousterman M; Cacoub P;
    Antivir Ther; 2010; 15(4):599-606. PubMed ID: 20587853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
    Hunyady B; Kovács B; Battyáni Z
    Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.